BACKGROUND: Current guidelines recommend pulmonary-vein isolation by means of catheter ablation as treatment for drug-refractory paroxysmal atrial fibrillation. Radiofrequency ablation is the most common method, and cryoballoon ablation is the second most frequently used technology. METHODS: We conducted a multicenter, randomized trial to determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomatic patients with drug-refractory paroxysmal atrial fibrillation. The primary efficacy end point in a time-to-event analysis was the first documented clinical failure (recurrence of atrial fibrillation, occurrence of atrial flutter or atrial tachycardia, use of antiarrhythmic drugs, or repeat ablation) following a 90-day period after the index ablation. The noninferiority margin was prespecified as a hazard ratio of 1.43. The primary safety end point was a composite of death, cerebrovascular events, or serious treatment-related adverse events. RESULTS: A total of 762 patients underwent randomization (378 assigned to cryoballoon ablation and 384 assigned to radiofrequency ablation). The mean duration of follow-up was 1.5 years. The primary efficacy end point occurred in 138 patients in the cryoballoon group and in 143 in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 34.6% and 35.9%, respectively; hazard ratio, 0.96; 95% confidence interval [CI], 0.76 to 1.22; P<0.001 for noninferiority). The primary safety end point occurred in 40 patients in the cryoballoon group and in 51 patients in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 10.2% and 12.8%, respectively; hazard ratio, 0.78; 95% CI, 0.52 to 1.18; P = 0.24). CONCLUSIONS: In this randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect to efficacy for the treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no significant difference between the two methods with regard to overall safety.

Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation / K. Kuck, J. Brugada, A. Fürnkranz, A. Metzner, F. Ouyang, K..R..J. Chun, A. Elvan, T. Arentz, K. Bestehorn, S.J. Pocock, J. Albenque, C. Tondo. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 374:23(2016), pp. 2235-2245. [10.1056/NEJMoa1602014]

Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation

C. Tondo
2016

Abstract

BACKGROUND: Current guidelines recommend pulmonary-vein isolation by means of catheter ablation as treatment for drug-refractory paroxysmal atrial fibrillation. Radiofrequency ablation is the most common method, and cryoballoon ablation is the second most frequently used technology. METHODS: We conducted a multicenter, randomized trial to determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomatic patients with drug-refractory paroxysmal atrial fibrillation. The primary efficacy end point in a time-to-event analysis was the first documented clinical failure (recurrence of atrial fibrillation, occurrence of atrial flutter or atrial tachycardia, use of antiarrhythmic drugs, or repeat ablation) following a 90-day period after the index ablation. The noninferiority margin was prespecified as a hazard ratio of 1.43. The primary safety end point was a composite of death, cerebrovascular events, or serious treatment-related adverse events. RESULTS: A total of 762 patients underwent randomization (378 assigned to cryoballoon ablation and 384 assigned to radiofrequency ablation). The mean duration of follow-up was 1.5 years. The primary efficacy end point occurred in 138 patients in the cryoballoon group and in 143 in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 34.6% and 35.9%, respectively; hazard ratio, 0.96; 95% confidence interval [CI], 0.76 to 1.22; P<0.001 for noninferiority). The primary safety end point occurred in 40 patients in the cryoballoon group and in 51 patients in the radiofrequency group (1-year Kaplan-Meier event rate estimates, 10.2% and 12.8%, respectively; hazard ratio, 0.78; 95% CI, 0.52 to 1.18; P = 0.24). CONCLUSIONS: In this randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect to efficacy for the treatment of patients with drug-refractory paroxysmal atrial fibrillation, and there was no significant difference between the two methods with regard to overall safety.
English
aged; atrial fibrillation; disease-free survival; female; follow-up studies; humans; Kaplan-Meier estimate; male; middle aged; postoperative complications; recurrence; reoperation; single-blind method; catheter ablation; cryosurgery; medicine (all)
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
Articolo
Esperti anonimi
Pubblicazione scientifica
2016
Massachussetts Medical Society
374
23
2235
2245
11
Pubblicato
Periodico con rilevanza internazionale
Aderisco
info:eu-repo/semantics/article
Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation / K. Kuck, J. Brugada, A. Fürnkranz, A. Metzner, F. Ouyang, K..R..J. Chun, A. Elvan, T. Arentz, K. Bestehorn, S.J. Pocock, J. Albenque, C. Tondo. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 374:23(2016), pp. 2235-2245. [10.1056/NEJMoa1602014]
reserved
Prodotti della ricerca::01 - Articolo su periodico
12
262
Article (author)
no
K. Karl-Heinz, B. Josep, F. Alexander, M. Andreas, O. Feifan, C. K. R. Julian, E. Arif, A. Thomas, B. Kurt, P. Stuart J., A. Jean-Paul, C. Tondo
File in questo prodotto:
File Dimensione Formato  
nejmoa1602014.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 722.98 kB
Formato Adobe PDF
722.98 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/534762
Citazioni
  • ???jsp.display-item.citation.pmc??? 319
  • Scopus 1330
  • ???jsp.display-item.citation.isi??? 1213
social impact